Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18764320 | 0.87 | RXRA (0.77) | RXRANR4A2MEN1KMT2ATDP1 | |
| SCHEMBL31516574 | 0.82 | RXRA (0.70) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL18764395 | 0.80 | RXRA (0.67) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL18764381 | 0.78 | RXRA (0.64) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL18764397 | 0.78 | RXRA (0.64) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL18764380 | 0.78 | RXRA (0.64) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL18764428 | 0.76 | PDE4B (0.63) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL18764360 | 0.75 | RXRA (1.00) | RXRANR4A2PDE4BPDE4DMEN1 | |
| SCHEMBL1227561 | 0.75 | RXRA (0.60) | RXRANR4A2MEN1KMT2AGAA | |
| SCHEMBL10073169 | 0.74 | RXRA (0.56) | RXRANR4A2PDE4BPDE4DMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2025-05-15 | — | — | US | disclosed |
| EP-4029857-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2022-07-20 | — | — | EP | disclosed |
| EP-3365329-B1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2022-03-30 | — | — | EP | disclosed |
| EP-3365329-B1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2022-03-30 | — | — | EP | disclosed |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2021-06-24 | — | — | US | disclosed |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2021-06-24 | — | — | US | disclosed |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | VASSILATIS DEMETRIOS K (GR) | 2021-03-16 | — | — | US | disclosed |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | VASSILATIS DEMETRIOS K (GR) | 2021-03-16 | — | — | US | disclosed |
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2018-11-01 | — | — | US | disclosed |
| EP-3365329-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NCOR1 | RXRA 7/4885NR4A2 1/4885PDE4B 1672/4885 |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | RXRA 7/4885NR4A2 1/4885PDE4B 1523/4885 |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | NR4A2, NR0B1, NR4A3 | RXRA 7/4885NR4A2 1/4885PDE4B 1523/4885 |
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | RXRA 7/4885NR4A2 1/4885PDE4B 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.